We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics

Download Mobile App

Fastest Ever Robotics-Driven COVID-19 Mass Testing Platform Gives 99% Accurate Results

By LabMedica International staff writers
Posted on 01 Dec 2020
Print article
Image: Fastest Ever Robotics-Driven COVID-19 Mass Testing Platform Gives 99% Accurate Results (Photo courtesy of Salient Bio)
Image: Fastest Ever Robotics-Driven COVID-19 Mass Testing Platform Gives 99% Accurate Results (Photo courtesy of Salient Bio)
A new robotics-driven COVID-19 mass testing platform that has been rolled out is up to three times faster than competitors for mass testing and aims to provide affordable, effective and easy-to-access pre-emptive diagnostic solutions for a range of medical conditions that facilitate early intervention and improve overall health outcomes.

Salient Bio (London, UK) has announced the commercial launch of its robotics-driven COVID-19 mass testing platform which facilitates COVID-secure environments at a quicker and more cost effective rate than the closest approved competitor, with a same day results notification process and a very cost effective per unit price for businesses conducting mass testing. The platform is reagent agnostic, meaning that disruption in supply chains can be mitigated by a shift to different reagent suppliers without it calling for wholesale infrastructure change at Salient’s labs, therefore limiting disruption and costs. Its accuracy, fast delivery and cost effectiveness make Salient Bio’s modular diagnostics platform ideal for sectors that require a safe environment for regular human contact, such as logistics, facilities management, education and manufacturing.

“With the rollout of vaccines likely to be staggered, rapid and accurate mass testing will play a vital role in the coming months in our immediate fight against COVID,” said Dr. Miles Priestman, Co-founder of Salient Bio. “Yet existing diagnostic labs often involve error prone manual processes – there is a huge opportunity to reinvent how they operate from the ground up. Using state of the art robotics and bespoke software development we hope to do just this, bringing significant cost and operational efficiency gains to help bring diagnostic labs fully into the 21st century.”

Related Links:
Salient Bio

Print article


Molecular Diagnostics

view channel
Image: Schematic representation of Chiari malformation type 1; it involves the lower part of the cerebellum known as tonsils, but not the brain stem (Photo courtesy of Healthline).

Common Brain Malformation Traced to Its Genetic Roots

About one in 100 children has a common brain disorder called Chiari 1 malformation, but most of the time such children grow up normally and no one suspects a problem. However about one in 10 of those children,... Read more


view channel
Image: uPath HER2 Dual ISH image analysis for breast cancer (Photo courtesy of Roche)

Roche Launches Digital Pathology Image Analysis Algorithms for Precision Patient Diagnosis in Breast Cancer

Roche (Basel, Switzerland) has announced the CE-IVD launch of its automated digital pathology algorithms, uPath HER2 (4B5) image analysis and uPath Dual ISH image analysis for breast cancer to help determine... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.